Skip to main content
. 2024 Aug 29;20(1):2395680. doi: 10.1080/21645515.2024.2395680

Figure 2.

Figure 2.

Long-term follow up of patients with nmCSPC (NCT00582140). Patients were followed for 15 y for significant medical events. Shown are the times at which patients developed documented metastatic disease (■), started androgen deprivation therapy (red), started a second generation AR targeted therapy (brown), or started docetaxel (blue). The time of death due to prostate cancer (●) or other cause (▲) is also shown. Subjects are ordered with respect to the pre-treatment PSA doubling time.